Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02340117
Title Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors SynerGene Therapeutics, Inc.
Indications

pancreatic adenocarcinoma

Therapies

SGT-53

Gemcitabine + Nab-paclitaxel

Age Groups: adult
Covered Countries USA


No variant requirements are available.